Repeat Offender: Bioniche Pharma Gets 2nd Warning Letter for Sotradecol Promotion
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says Bioniche must adopt new policies to monitor promotional activities because existing ones seem insufficient.